Jafron Biomedical Co. Ltd. (300529)
SZSE
14.97
-0.25 (-1.64%)
Closed
Sep 11, 2026
Day's Range
14.9015.27
52 wk Range
14.7324.26
Financial Statements - 300529 - Jafron Biomedical Co. Ltd.
Revenue
2.01B▼ 24.9%
Net Income
531.67M▼ 34.7%Net Margin 26.4%
EBITDA
896.70M▼ 25.6%
Free Cash Flow
548.62M▼ 32.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 2.01B | 2.67B | 1.92B | 2.49B | 2.67B | 1.95B |
| Cost of Goods | 428.50M | 514.60M | 383.98M | 440.10M | 402.06M | 287.96M |
| Gross Profit | 1.58B | 2.16B | 1.53B | 2.05B | 2.27B | 1.66B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 739.52M | 1.04B | 523.15M | 1B | 1.38B | 1.01B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 660.12M | 1B | 521.02M | 1.01B | 1.40B | 1.03B |
| Income Tax | 128.45M | 192.77M | 95.29M | 135.86M | 211.37M | 158.95M |
| Net Income | 531.67M | 814.18M | 425.72M | 880.94M | 1.19B | 872.99M |
| EPS Basic | 0.69 | 1.05 | 0.55 | 1.12 | 1.49 | 1.1 |
| EPS Diluted | 0.69 | 1.05 | 0.55 | 1.12 | 1.49 | 1.08 |
| Basic Shares Outstanding | 772.20M | 781.13M | 793.62M | 794.25M | 803.23M | 795.67M |
| Diluted Shares Outstanding | 772.20M | 781.13M | 793.62M | 794.25M | 803.23M | 795.67M |
| Ebit | 713.63M | 1.07B | 575.35M | 1.05B | 1.41B | 1.01B |
| Ebitda | 896.70M | 1.20B | 683.37M | 1.13B | 1.47B | 1.05B |
| Net Income Continuous Operations | 531.67M | 814.18M | 425.72M | 880.94M | 1.19B | 872.99M |
| Minority Interests | 1.15M | 6M | 10.76M | 8.61M | 971.91K | 2.24M |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
